Advanced Wound Care Summit Europe 2022
It was an honour to present at the Advanced Wound Care Summit Europe conference this week. Our extensive knowledge and library of clinical trials and our history as the experienced leader of Cold Plasma medicine was presented to the audience to bring light to the positive benefits of Adtec Cold Plasma devices.
If you would like to hear more about our efficacy and strengths for wounds, surgical site infections and medical dermatology, send us a PM or email us at info@adtecplasma.com
Presentation at the DFSG 2022
We're so excited for exhibiting at the Diabetic Foot Study Group (DFSG) conference next week. Please be sure to visit us at booth no.11 where we will based during the conference. We welcome you to see our SteriPlas Cold Plasma medical device live in action.
We're also excited to announce that the Diabetes Team at Kettering General Hospital NHS Foundation Trust will have a poster presentation illustrating the strong antibacterial efficacy and healing qualities of the Adtec SteriPlas for diabetic foot ulcers.
The poster, "DGH EXPERIENCE OF USING COLD PLASMA MEDICAL DEVICE AS AN ADJUNCT THERAPY TO ANTIMICROBIALS IN TREATING CHRONIC NON HEALING INFECTED DIABETIC FOOT ULCERS" will be presented by Jemma Cruickshank on Saturday 17th September, 13:25 - 14:25.
See you all soon!
Antimicrobial (antibiotic) Resistance – the drugs won’t work !
Antimicrobial resistance (AMR) poses a significant global threat of far-reaching proportions. It is estimated that drug resistant infections contribute to nearly 5 million deaths every year and predicted to increase to over 10 million deaths every year. WHO has declared that AMR is one of the top 10 global public health threats facing humanity.
(The worldwide total deaths from COVID is now just over 6 million and we all know how frightening it was before the vaccine was developed)
AMR occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines making infections harder to treat and increasing the risk of disease spread, severe illness and death. As a result, the medicines become ineffective and infections persist in the body, increasing the risk of spread to others. Microorganisms that develop antimicrobial resistance are sometimes referred to as “superbugs”. Without effective antimicrobials, the success of modern medicine in treating infections, including during major surgery and cancer chemotherapy, would be at increased risk. Chronic infections if left untreated could result in tissue damage, amputation, longer stays in hospitals, surgical interventions, or increased possibility of mortality. Patients who are infected with drug-resistant infections are more likely to develop complications and are up to three times more likely to die from the infection. Non-healing wounds in particular, are characterised by complex and mixed bacterial populations, often involving antibiotic-resistant bacteria as well as phenotypically tolerant bacteria in biofilm form. The biofilm factor is clearly of considerable clinical importance: it protects bacteria from antimicrobial agents leading to persistent and difficult to treat chronic infections, and it exacerbates the spread of antibiotic resistance. Surgical Site Infections are also linked to anti-microbial resistance.
SteriPlas cold plasma technology kills bacteria by a physical mode of action and bacteria are therefore unlikely to develop primary or secondary resistance, which we have documented from our clinical studies. SteriPlas cold plasma also kills antibiotic resistant bacteria (e.g. MRSA) and kills bacteria encased in biofilm which are typically up to 1000 times more resistant to antibiotics. SteriPlas has proven clinical efficacy in treating wound infections, diabetic foot infections and surgical site infections in all clinical studies, all with the bonus of no side effects reported.
SteriPlas cold plasma can be used to treat topical infections reserving antibiotics for severe systemic infections.
References
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext
https://www.worldometers.info/coronavirus/
https://www.who.int/health-topics/antimicrobial-resistance
https://healthfirsteurope.eu/wp-content/uploads/2020/11/A3A4-48pp-Booklet-Spreads-1.pdf
Bowler, P., Murphy, C. & Wolcott, R. Biofilm exacerbates antibiotic resistance: Is this a current oversight in antimicrobial stewardship?. Antimicrob Resist Infect Control 9, 162 (2020).
Diabetic Foot Study Group Conference
Are you excited as we are?
Looking forward to resuming exhibition season at the Diabetic Foot Study Group conference in Slovakia.
We'll be exhibiting between 16-18 Sept with our Adtec SteriPlas on demonstration ready to show you just how quick and effective it is to use and combat antibiotic resistant bacteria within diabetic foot ulcers.
Adtec Healthcare prepares for exhibition in July
We are very excited to be exhibiting at the Malvern Diabetic Foot Conference between 7-9th July. This will be our first physical exhibition participation in over a year! Be sure to visit us and see our cold plasma medical device live in action, perfect for the treatment of chronic DFUs infected with biofilm.
LVAD - Heidelberg publication 2021
Congratulations to Dr Kremer and the Cardiology Team at The University Hospital Heidelberg for their new publication, “Follow-Up after Cold Atmospheric Argon Plasma for Wound Management of Driveline Infections - A Promising Strategy”. This publication features the use of our Adtec SteriPlas medical device for the treatment of driveline infections (DLI). The results demonstrate how the safety, reliability and painless treatment from the Adtec SteriPlas can significantly reduce the wound and infection around the DLI, with the opportunity for sustainable freedom from DLI.
SteriPlas treatment for Acne Vulgaris
We are excited to announce the recent publication, “Cold atmospheric plasma (CAP) as a promising therapeutic option for mild to moderate acne vulgaris” which features our Adtec SteriPlas cold plasma for the treatment of acne.
The paper created by Dr Mariachiara Arisi from the Department of Dermatology at the University of Brescia, Italy demonstrates the antibacterial efficacy of our patented cold plasma for the treatment of acne vulgaris patients. It indicates the significant reduction of acne skin lesions in treated patients who were previously unsuccessful treated with topical drugs. Unlike topical drugs, the Adtec SteriPlas demonstrated a safe, effective, and well-tolerated treatment option with no side effects for the treatment of acne patients.
No adverse effects or skin reactions were reported either during the treatment nor at 3-months follow-up. Treatment was completely painless and well tolerated. Patients did not report itching or burning sensation during plasma application and in the following days.
The full paper can be found here: https://www.sciencedirect.com/science/article/pii/S2212816620300172
Adtec Healthcare's new project with Hull York Medical School testing gas plasma on Osteomyelitis bone infections.
We are excited to announce the study “Gas Plasma for the Prevention and Management of Osteomyelitis Biofilms” has now begun at the Hull York Medical School. The study led by Dr Angela Oates and funded by the National Biofilms Innovation Centre will seek to test the efficacy of our gas plasma system on osteomyelitis bone infections using our PlasmaTact device. This project will develop a novel laboratory testing model to evaluate and optimise plasma treatment for osteomyelitis biofilm infections.
We have already demonstrated that our gas plasma medical device, the Adtec SteriPlas, has proven antibacterial efficacy and accelerated healing in problematic and non-healing wounds with strong evidence collected from our extensive library of clinical trials and publications. This includes diabetic foot ulcers which are often complicated by biofilm. Over the course of its existence it has shown that no side effects have been reported which offers patients a safe and reliable treatment option. It has also shown that a 2-minute treatment time is sufficient to achieve exceptional results and that it is also a broad spectrum antibacterial with the ability to kill a wide range of Gram-negative and Gram-positive bacterial superinfections.
The PlasmaTact utilizes the same gas plasma technology from the Adtec SteriPlas. The main difference between the two devices is that the PlasmaTact offers a smaller handheld style treatment area of 1cm2 (vs 12cm2 with the SteriPlas) and offers users the ability to change the power output settings (vs the fixed settings with the SteriPlas).
Osteomyelitis (OM) is biofilm infection of the bone and is a common and costly complication in diabetic foot ulcer (DFU) patients often resulting in amputations. Long-term antimicrobial therapy is widely used as a primary treatment for OM or as an adjunct to surgical approaches however, there is a failure rate of up to 35% and an associated increasing prevalence of antimicrobial resistance. There is an urgent clinical need to develop alternative non-antimicrobial approaches to treat infections, and currently there is a lack of credible alternatives in the market for the treatment of OM.
Evaluating the efficacy of gas plasma in OM represents unique challenges as both the biofilm growth and physical characteristics of OM bone will affect the delivery and activity of the plasma. In vitro biofilm model systems offer a means by which rapid, costs effective and standardised evaluation of anti-biofilm treatments can be undertaken.
The PATROL project is a new and exciting collaborative project between Adtec Healthcare and Dr Angela Oates of the University of Hull Wound Healing Group which is supported by NBIC PoC Award. The overall aim of this project is to develop an osteomyelitis biofilm infection model to support the optimisation and evaluation of a cold plasma technology for the management and prevention of OM.
This collaborative project represents the first phase of the novel utilisation of Adtec SteriPlas to treat OM or as an adjunct current therapy. Successful translation of this technology to treat OM will reduce antimicrobial usage and associated OM amputations, reducing NHS costs and ultimately improving patient outcomes.
#osteomyelitis #biofilm #boneinfection #infection #antimicrobial #antimicrobialresistance #amputation #plasma #gasplasma #coldplasma #kaltesplasma #NBIC #universityofhull #podiatry #diabeticfootulcer #diabeticfoot #diabetes #hullyorkmedicalschool
Mr Keith Cutting presents significant results on DFUs in Vienna conference
Mr Keith Cutting presented at The European Conference on Controversies in Diabetic Foot Management conference in Vienna last week. His presentation focused on the benefits of treating complex diabetic foot ulcer patients with the Adtec SteriPlas.
The Adtec SteriPlas has shown promising results leading to healing in problematic and non-healing wounds such as diabetic foot ulcers or surgical site infections. These complex wounds that have shown signs of stalled healing respond well to intervention with the Adtec SteriPlas.
To learn more about our medical device and the benefits it offers to patients with wounds, surgical site infections and dermatological conditions send us an email at info@adtec.eu.com
Promising results for the treatment of diabetic foot ulcers using the Adtec SteriPlas
We are excited to show you a recent conference poster presented at the BSAC Spring 2019 conference, submitted by Kettering General Hospital NHS Foundation Trust.
The poster shows the promising results of the using the Adtec SteriPlas on diabetic foot ulcers that are stalled by biofilm. The SteriPlas “is postulated as an alternative for antibiotics for patients where antibiotic therapy is difficult (due to resistance or adverse effects) or as an adjunct treatment for patients with chronic wounds including those with biofilms”.
Contact us at info@adtec.eu.com to learn more about how the Adtec SteriPlas may benefit your non-healing wound patients.
